Butterworth Labs adopts COVID-19 crisis measures

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/appledesign)
(Image: Getty/appledesign)

Related tags: Drug development, COVID-19, Coronavirus

The pharmaceutical analysis firm is continuing its contract analytical laboratory services running, with changes designed to keep people and products safe.

Justin Robinson, marketing and business development manager at the company, told Outsourcing-Pharma that while maintaining the supply chain of vital treatments is challenging enough in normal times, difficulties presented by the global pandemic make the process even more difficult.

His company and clients, though, have looked at ways to balance a need to continue operation with protecting personnel during the crisis.

Like us, most of our clients have instigated social distancing as much as possible in the workplace and this has reduced their capacity for work so they have been outsourcing more than usual. Some companies have additional work as they research new products to treat the Covid-19 symptoms and vaccines, so they have the double whammy of fewer staff available at any time and increased workload​,” he said.

Additionally, Robinson explained, numerous customers have requested Butterworth Labs complete Covid-19 risk assessments. These typically address concerns like reliability of the supply chain for laboratory consumables, contingencies for potential staff illness, and preparation for any potential stricter lockdown. 

These are all issues that our leadership team have addressed and mitigated as best as possible​,” he added.

Actions taken by Butterworth Labs include:

  • Closing their administration site, located in Hampton, and permitting staff to work from home.
  • Analysts required to maintain laboratory operations will work in a shift pattern reducing the number of staff onsite at once, allowing for better social distancing.
  • Implementing cross training of laboratory staff for greater staffing flexibility.
  • Exchanging face-to-face meetings for video conferences.

“If the current situation changes we may need to revise these plans, but at present our new operations are running smoothly and uninterrupted.  In fact, we even have some spare capacity at present, however, as a laboratory proving key services to the pharmaceutical industry we may need to prioritize new work to ensure the manufacture and release of critical drugs​,” Robinson added.

Robinson also told us that Butterworth Labs is shoring up its own supply by storing additional stocks of consumables where appropriate, and continuing to use a diverse range of suppliers.

Related news

Show more

Related products

show more

Q&A: Effective Drug Product Process Development

Q&A: Effective Drug Product Process Development

Catalent Pharma Solutions | 14-Jan-2021 | Insight Guide

In this Q&A, a Catalent Biologics expert shares his expertise with drug product process development challenges, risks and how to mitigate them, the...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us


View more